在2020年EHA会议上,Michael J. Dickinson 就CD20-TCB在复发或难治性(R / R)非霍奇金淋巴瘤(NHL)中I期临床试验中的疗效和安全性做了口头报告(Abstract: S241 )。CD20-TCB(RG6026)是一种新型的T细胞接合双特异性抗体,包含两个CD20片段抗原...
Responding patients showed long-term T-cell activation after the first infusion of CD20-TCB at doses from 0.6mg and above. T-cell activation was demonstrated by 2-4-fold elevation of T-cell activation markers such as Ki67, HLA-DR, PD-1, ICOS, OX40, and 4-1BB, which was sustained ...
Conclusions: CD20‐TCB is a novel 2:1 format T‐cell‐engaging bispecific antibody which displays highly promising clinical activity in heavily‐pretreated NHL. Keywords: B‐cell lymphoma; CD20; immune system. Disclosures: Dickinson, M: Consultant Advisory Role: Roche; Honoraria: Roche. Morsch...
描述: 格菲妥单抗。关键字: RO7082859 |RG 6026 |CD20-TCB;RO7082859 |RG 6026 |CD20-TCB | 原创作者:上海陶术生物科技有限公司 标签:格菲妥单抗 Glofitamab;格菲妥单抗RO7082859|||RG 6026|||CD20-TCB;RO7082859|||RG 6026|||CD20-TCB产品询价/message 留言框 感兴趣的产品: * 您的单位: * 您的...
CD20-TCBBispecific T-cell recruiting antibodies are emerging as a potent immunotherapeutic class in the treatment of B-cell malignancies and act by simultaneously targeting antigens on T-cells and malignant cells to effect tumor cell death. Glofitamab is a novel full-length IgG-like CD20-CD3 ...